The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BSH 2017 | What are the challenges of allogeneic stem cell transplant in myeloma?
Martin Kaiser, MD, from the Institute of Cancer Research, London, UK, discusses the challenges of allogeneic stem cell transplant in myeloma at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. He describes the main challenges of high toxicity and risk of relapse, and points out that transplants are only considered for young and reasonably fit patients, which excludes the majority of the myeloma patient population. Dr Kaiser outlines discussions on which patients benefit from allogeneic stem cell transplants in myeloma, taking into consideration genetic factors and risk group. He concludes that decisions about a transplant should be driven by the patient.
